Cabot
CBT
75.41
-1.70
-2.20%
Cabot
US · CBT
#2289 by market cap
Listed 1970
75.41
-1.70
-2.20%
Live - 5344 symbols - heartbeat 431s ago
· 2026-10-08 07:00
Pre-market
75.00
-0.54%
After-hours
75.41
0.00%
- Market cap
- 3.89B
- P/E (TTM)i
- 21.12
- P/Bi
- 2.43
- EPSi
- 6.02
- Div yieldi
- 2.42%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on CBT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.47, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -7.04% YoY
Margins
- Gross margin
- 25.32%
- Operating margin
- 16.73%
- Net margin
- 8.78%
Key ratios & quality
- Enterprise valuei
- 4.77B
- PEG ratioi
- 1.28
- Altman Z-Scorei
- 3.47
PEG uses trailing P/E against the 3-year net income growth rate (16.56%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.24B | 3.34B | 2.61B | 3.41B | 4.32B | 3.93B | 3.99B | 3.71B |
| Gross profit | 772.00M | 685.00M | 500.00M | 799.00M | 885.00M | 839.00M | 960.00M | 940.00M |
| Selling & admin expenses | 308.00M | 290.00M | 292.00M | 289.00M | 258.00M | 253.00M | 283.00M | 260.00M |
| Research & development | 66.00M | 60.00M | 57.00M | 56.00M | 55.00M | 57.00M | 63.00M | 59.00M |
| Operating profit | 398.00M | 335.00M | 151.00M | 454.00M | 572.00M | 529.00M | 614.00M | 621.00M |
| Pretax profit | 117.00M | 255.00M | -33.00M | 406.00M | 335.00M | 451.00M | 529.00M | 565.00M |
| Tax | 193.00M | 70.00M | 191.00M | 123.00M | 102.00M | -28.00M | 111.00M | 196.00M |
| Net profit | -74.00M | 186.00M | -221.00M | 286.00M | 243.00M | 484.00M | 424.00M | 376.00M |
| Basic EPS | -2 | 3 | -4 | 4 | 4 | 8 | 7 | 6 |
| Diluted EPS | -1.85 | 2.63 | -4.21 | 4.34 | 3.62 | 7.73 | 6.72 | 6.02 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 936.00M | 923.00M | 899.00M | 849.00M | 904.00M | 982.00M |
| Gross profit | 241.00M | 244.00M | 220.00M | 211.00M | 210.00M | 184.00M |
| Selling & admin expenses | 64.00M | 62.00M | 68.00M | 69.00M | 67.00M | 73.00M |
| Research & development | 15.00M | 15.00M | 15.00M | 13.00M | 14.00M | 13.00M |
| Operating profit | 162.00M | 167.00M | 137.00M | 129.00M | 129.00M | 98.00M |
| Pretax profit | 151.00M | 155.00M | 115.00M | 118.00M | 120.00M | 58.00M |
| Tax | 49.00M | 43.00M | 63.00M | 37.00M | 44.00M | 46.00M |
| Net profit | 105.00M | 113.00M | 54.00M | 82.00M | 78.00M | 14.00M |
| Basic EPS | 2 | 2 | 1 | 1 | 1 | 0 |
| Diluted EPS | 1.69 | 1.86 | 0.79 | 1.37 | 1.27 | 0.12 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.39B | 1.21B | 978.00M | 1.43B | 1.82B | 1.63B | 1.61B | 1.54B |
| Cash & ST investments | 175.00M | 169.00M | 151.00M | 168.00M | 206.00M | 238.00M | 223.00M | 258.00M |
| Inventory | 511.00M | 466.00M | 359.00M | 523.00M | 664.00M | 585.00M | 552.00M | 504.00M |
| Total assets | 3.24B | 3.00B | 2.78B | 3.31B | 3.53B | 3.60B | 3.74B | 3.82B |
| Total current liabilities | 952.00M | 599.00M | 529.00M | 1.15B | 1.11B | 822.00M | 772.00M | 957.00M |
| Short-term debt | 284.00M | 40.00M | 21.00M | 445.00M | 354.00M | 182.00M | 53.00M | 274.00M |
| Long-term debt | 719.00M | 1.02B | 1.09B | 717.00M | 1.09B | 1.09B | 1.09B | 856.00M |
| Total liabilities | 1,965,000,000.00 | 1,870,000,000.00 | 1,967,000,000.00 | 2,216,000,000.00 | 2,493,000,000.00 | 2,197,000,000.00 | 2,146,000,000.00 | 2,110,000,000.00 |
| Total equity | 1.28B | 1.13B | 814.00M | 1.09B | 1.03B | 1.41B | 1.59B | 1.71B |
| Retained earnings | 1.42B | 1.34B | 989.00M | 1.16B | 1.28B | 1.57B | 1.73B | 1.84B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.60B | 1.57B | 1.54B | 1.46B | 1.55B | 1.67B |
| Cash & ST investments | 213.00M | 239.00M | 258.00M | 230.00M | 252.00M | 250.00M |
| Inventory | 541.00M | 531.00M | 504.00M | 503.00M | 522.00M | 566.00M |
| Total assets | 3.78B | 3.84B | 3.82B | 3.76B | 3.90B | 3.98B |
| Total current liabilities | 818.00M | 740.00M | 957.00M | 874.00M | 1.07B | 1.14B |
| Short-term debt | 199.00M | 110.00M | 274.00M | 272.00M | 436.00M | 445.00M |
| Long-term debt | 1.09B | 1.11B | 856.00M | 854.00M | 863.00M | 828.00M |
| Total liabilities | 2,194,000,000.00 | 2,154,000,000.00 | 2,110,000,000.00 | 2,028,000,000.00 | 2,210,000,000.00 | 2,241,000,000.00 |
| Total equity | 1.59B | 1.68B | 1.71B | 1.73B | 1.69B | 1.73B |
| Retained earnings | 1.80B | 1.85B | 1.84B | 1.84B | 1.84B | 1.82B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 298.00M | 363.00M | 377.00M | 257.00M | 100.00M | 595.00M | 692.00M | 665.00M |
| Depreciation & amortization | 149.00M | 148.00M | 158.00M | 160.00M | 146.00M | 144.00M | 151.00M | 154.00M |
| Free cash flow | 69.00M | 139.00M | 177.00M | 62.00M | -111.00M | 351.00M | 451.00M | 391.00M |
| Dividends paid | -80.00M | -80.00M | -80.00M | -80.00M | -84.00M | -88.00M | -93.00M | -96.00M |
| Stock buybacks / issuance | -120.00M | -169.00M | -41.00M | 3.00M | -47.00M | -94.00M | -152.00M | -160.00M |
| Ending cash balance | 175.00M | 169.00M | 151.00M | 170.00M | 206.00M | 238.00M | 223.00M | 258.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 73.00M | 249.00M | 219.00M | 126.00M | 77.00M | 75.00M |
| Depreciation & amortization | 38.00M | 39.00M | 40.00M | 41.00M | 49.00M | 50.00M |
| Free cash flow | -26.00M | 215.00M | 155.00M | 57.00M | 32.00M | 37.00M |
| Dividends paid | -23.00M | -24.00M | -25.00M | -24.00M | -24.00M | -24.00M |
| Stock buybacks / issuance | -47.00M | -40.00M | -33.00M | -52.00M | -49.00M | 0 |
| Ending cash balance | 213.00M | 239.00M | 258.00M | 230.00M | 252.00M | 251.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -8.66 | 14.41 | -28.18 | 30.16 | 22.33 | 40.43 | 27.82 | 21.92 |
| ROA %i | -3.48 | 4.96 | -8.23 | 8.12 | 6.03 | 12.26 | 10.19 | 8.63 |
| ROIC %i | -3.59 | 9.05 | -10.37 | 13.49 | 10.29 | 19.05 | 15.64 | 13.21 |
| 5-year avg ROE %i | 1.97 | 2.83 | 1.40 | 5.10 | 6.03 | 15.83 | 18.51 | 28.53 |
| EBIT margin %i | 5.27 | 9.41 | 0.77 | 13.35 | 9.05 | 13.76 | 15.27 | 17.26 |
| FCF / sales %i | 2.13 | 4.17 | 6.77 | 1.82 | -- | 8.93 | 11.29 | 10.53 |
| Current ratioi | 1.46 | 2.02 | 1.85 | 1.24 | 1.65 | 1.98 | 2.08 | 1.61 |
| Quick ratioi | 0.85 | 1.17 | 1.08 | 0.71 | 0.94 | 1.14 | 1.24 | 0.97 |
| Debt / assetsi | 30.92 | 35.42 | 43.29 | 37.69 | 43.29 | 37.74 | 32.87 | 31.85 |
| LT debt / equityi | 62.31 | 102.61 | 171.20 | 84.58 | 130.51 | 93.20 | 82.46 | 60.71 |
| Interest coveragei | 3.17 | 5.32 | 0.38 | 9.29 | 6.98 | 6.01 | 7.53 | 8.43 |
| Revenue CAGR (3Y) %i | 4.13 | 11.44 | -1.28 | 1.69 | 9.00 | 14.57 | 5.42 | -4.93 |
| Net income CAGR (3Y) %i | -- | 2.22 | -- | -- | 10.01 | -- | 14.98 | 16.56 |
| FCF CAGR (3Y) %i | -42.24 | -20.82 | -4.15 | -3.50 | -- | 25.64 | 93.76 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 30.49 | 28.96 | 21.92 | 20.81 | 18.76 | 11.89 |
| ROA %i | 11.54 | 11.27 | 8.63 | 8.27 | 7.32 | 4.79 |
| ROIC %i | 17.60 | 17.39 | 13.21 | 12.80 | 11.13 | 7.60 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.97 | 17.30 | 17.26 | 17.05 | 16.31 | 13.35 |
| FCF / sales %i | 7.37 | 9.12 | 10.53 | 11.12 | 12.84 | 7.73 |
| Current ratioi | 1.96 | 2.13 | 1.61 | 1.67 | 1.45 | 1.47 |
| Quick ratioi | 1.16 | 1.25 | 0.97 | 0.97 | 0.85 | 0.86 |
| Debt / assetsi | 34.06 | 31.67 | 31.85 | 29.97 | 33.33 | 32.03 |
| LT debt / equityi | 76.38 | 71.71 | 60.71 | 54.22 | 55.04 | 51.59 |
| Interest coveragei | 8.84 | 8.80 | 8.43 | 8.09 | 7.77 | 6.55 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Reinforcement Materials is the largest reported line at 61.00% of revenue, across 3 reported segments.
- Performance Chemicals follows at 35.74%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Reinforcement Materials61.00%
Performance Chemicals35.74%
Unallocated and Other3.26%
Quote time 2026-10-08 07:00:03 · For reference only, not investment advice and not tailored to your situation.